GENOMENON

Ann Arbor,  MI 
United States
https://www.genomenon.com/
  • Booth: 1323

Genomenon's Mastermind Genomic Search Engine has indexed over 5.5M full text scientific articles from medical journals to provide a prioritized, comprehensive search into the genomic literature for every disease, gene and variant.  Mastermind has a Google-like front end to search publications, and results are delivered in a format specifically designed for clinical users to quickly find the most relevant information needed to interpret the patient’s data.  

Ask us about Mastermind Alerts for weekly updates on your search criteria and Mastermind Evidence-based Panel Design. 

Brands: Mastermind Genomic Search Engine, Mastermind Alerts, Mastermind VCF Annotation, Mastermind Biomarker Discovery Service


 Press Releases

  • Mastermind Genomic Search Engine to Provide Direct Links to Genomic Evidence within SOPHiA’s Solutions

    Genomenon® announced today at the American Society of Human Genetics Annual Meeting (ASHG) a partnership with SOPHiA GENETICS that includes incorporating the Mastermind® Genomic Search Engine into the SOPHiA Platform and the Alamut Suite. The partnership puts the most up-to-date genomic research at the fingertips of clinical researchers performing genomic analysis worldwide.

    The SOPHiA Platform is the technology of choice for streamlined Data-Driven Medicine, including clinical-grade genomic analysis, interpretation, and reporting. SOPHiA has been adopted by 1,000 healthcare institutions to date, and analyzed more than 420,000 genomic profiles – 16,000 new profiles processed each month. The Alamut Suite powered by SOPHiA is a decision-support software designed to explore and investigate variations of the human genome. Alamut helps clinical researchers in the complex tasks of genomic variants annotations, filtration and exploration.

    With the addition of Mastermind, users of both technologies will be able to quickly access the genomic evidence associated with human variants, shortening the search time required to interpret a variant and assess its pathogenicity.

    This partnership will allow SOPHiA’s users to see a wider picture of the detected variants. A key driver in the decision is the breadth and depth of Mastermind’s coverage of genomic variants and published literature. Mastermind has indexed over 7 million full text articles and 600,000 supplemental data sets andcovers over 5.7 million variants found in the medical literature.

    This partnership will help experts better and more quickly assess the impact of accurately detected genomic variants in a clinical context. We are thrilled to be able to provide our users with all the necessary information they need to make the best possible decision for each case,” said Gioia Althoff, Senior Vice President, Genomics for SOPHiA.

    We’re excited to partner with SOPHiA to put the most comprehensive and up-to-date genomic research in the hands of geneticists and researchers performing genomic analysis.” said Mike Klein, CEO of Genomenon. “The broader adoption of Genomenon’s Mastermindprovides significant value to our fast growing customer base around the world.

    About Genomenon

    Genomenon connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases. Our flagship product, the Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield and assure repeatability in reporting genetic testing results. We license our Mastermind Curated Genomic Datasets to pharmaceuticaland bio-pharma companies to inform precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

    About SOPHiA Genetics

    A leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company that developed SOPHiA, an advanced AI technology helping healthcare professionals make sense of the large amount of clinical data. SOPHiA GENETICS is democratizing Data-Driven Medicine by enabling the rapid adoption of genomic and radiomic analysis worldwide, turning data into actionable insights, and sharing knowledge through its community of over 990 healthcare institutions in 82 countries in a sustainable and inclusive way. The company’s achievements and innovative approach is recognized by the MIT Technology Review”50 Smartest Companies”.

    For more information, visit www.sophiagenetics.com

  • Partnership with Genomenon Includes Placing Mastermind Genomic Search Engine at UK’s National Health Service (NHS)

    Genomenon announced a partnership with Congenica Ltd today that incorporates Mastermind® Genomic Search Engine results into Congenica’s industry-leading clinical decision support platform for genomic data interpretation. The goal of the partnership is to put the most up-to-date genomic research at the fingertips of geneticists diagnosing genetic diseases.

    Congenica® is state-of-the-art software for the analysis and interpretation of complex genomic data, enabling healthcare professionals to increase diagnostic yield and case throughput, maximize their workflow efficiency and improve confidence in every diagnosis. Interpreted genomic data from Congenica supports rapid and accurate diagnoses, helping to provide patients with the treatment they need, faster than ever before.

    With this partnership, Mastermind will be available to all Congenica users, including the UK’s National Health Service (NHS) as part of Congenica’s arrangement as the exclusive decision support platform provider for the NHS Genomic Medicine Service. Each Congenica user at the national network of UK laboratories that provide genetic testing for NHS patients will be given access to Mastermind Professional Edition, directly integrated within the Congenica platform.

    Congenica users will be able to quickly access the genetic evidence associated with their patients’ variants and, with a single click, gain access to the full list of articles within Mastermind to shorten the search time required to clinically interpret a variant and support its pathogenicity. A key driver in the decision to incorporate Mastermind is the breadth and depth of its coverage of genetic variants and published literature. Mastermind has indexed nearly 7 million full text articles and 500,000 supplemental data sets and covers over 4.9 million variants found in the medical literature.

    “Mastermind brings a new dimension to the Congenica platform, aiding variant interpretation by reducing the manual effort required to curate the rapidly growing body of genomic research, improving the likelihood of finding key genetic insights that could be critical for diagnosis.” said David Atkins, CEO of Congenica. “We believe that our growing number of global users will find a great deal of benefit from having Mastermind available with the Congenica platform.”

    “We’re thrilled to partner with Congenica to put the most comprehensive and up-to-date genetic research in the hands of geneticists making clinical diagnoses.” said Mike Klein, CEO of Genomenon. “Our relationship extends Mastermind’s global reach, and coupled with Congenica, provides significant value in cutting turnaround time and increasing diagnostic yield for genetic labs.”

    About Genomenon

    Genomenon connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases.

    Our flagship product, the Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield and assure repeatability in reporting genetic testing results.

    We license our Mastermind Curated Genomic Datasets to pharmaceutical and bio-pharma companies to inform precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

    About Congenica

    Congenica is a digital health technology company with the world’s leading clinical decision support platform for accelerated genomic data interpretation. Congenica software enables genomic medicine by integrating genetic data into healthcare, empowering clinicians to provide life-changing answers that transform the lives of individuals, patients and their families.

    Genetic diseases are technically difficult to diagnose, and patients often spend years waiting for a diagnosis. Congenica convert genomic data into actionable information, expediting the process through more efficient and accurate analysis. This supports healthcare professionals in providing patients with robust diagnoses and precise, personalized care.

    Born out of pioneering research from the Wellcome Sanger Institute and the NHS, Congenica is headquartered in Cambridge, UK, with a global footprint across the US and China. The Congenica platform is validated by the pivotal Genomics England 100,000 Genomes Project and is the exclusive clinical interpretation partner for the NHS Genomic Medicine Service.

    For more information, visit congenica.com.

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.